Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2020-04-24 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2020年第一季度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (367 characters) stating that the company's 2020 first quarter report will be published on a specific date and website. It does not contain the actual financial data or report itself, but only informs investors about the upcoming release. According to the 'MENU VS MEAL' rule, such a brief notice about report publication is classified as a Report Publication Announcement (RPA).
2020-04-24 Chinese
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2019 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the meeting date, attendance, voting results on various proposals including the 2019 annual reports, audit reports, profit distribution, and appointment of auditors. The document includes voting outcomes and legal opinions on the meeting's validity. It does not contain the full annual report or financial statements but references that these reports were published separately on the China Securities Regulatory Commission designated website. The document is essentially an official announcement of the AGM resolutions and voting results rather than the full report itself. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5,000 characters, consistent with a detailed voting results announcement rather than a full report.
2020-04-24 Chinese
2019年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the validity of the resolutions passed at the meeting. The document does not contain financial statements or detailed financial performance data but focuses on the legal compliance and procedural aspects of the AGM. This matches the definition of 'AGM Information' which includes presentations and materials shared during the AGM. The document length is 5575 characters, which is sufficient to be a substantive legal opinion rather than a brief announcement. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-04-24 Chinese
关于召开2019年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2019 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on (including the 2019 annual report, audit report, financial statements, and profit distribution plan), registration details, and proxy forms. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for shareholders to participate in the AGM. The document length is about 4901 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and meeting details.
2020-04-21 Chinese
2019年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2019 年年度报告全文" which translates to "2019 Annual Report Full Text" for 福安药业（集团）股份有限公司 (Fuan Pharmaceutical Group Co., Ltd.). It contains comprehensive sections typical of an annual report, including company overview, financial data, risk factors, business summary, management discussion, and financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial figures, management discussion, and company information confirms it is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2020-03-27 Chinese
独立董事关于第四届董事会第十二次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on various company matters related to the 2019 fiscal year, including internal control evaluation, use of raised funds, related party transactions, profit distribution plan, audit firm reappointment, accounting policy changes, and cash management. It references compliance with regulatory requirements and company bylaws, and it is dated March 27, 2020. The document is not a full annual report but rather an independent opinion on specific governance and financial matters discussed at a board meeting. It does not contain full financial statements or comprehensive financial analysis. This type of document aligns with Audit Report / Information (AR) filings, which include audit opinions, internal control evaluations, and related independent assessments. The document length is short (1911 characters), but it contains substantive independent opinions rather than just an announcement or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR with high confidence. FY 2019
2020-03-27 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.